eLife Latest: Authors can now submit a manuscript to the journal and medRxiv at the same time

As eLife transitions to exclusively reviewing preprints, we have integrated medRxiv into our submission process for the rapid sharing of new medical research.

Last year was an eventful one for eLife, as we took the latest steps in our efforts to drive change in scientific and medical publishing. In December, we announced our shift towards a new ‘publish, then review’ model for science publishing, in which the journal will exclusively review research submitted as preprints from authors who choose to have their work reviewed by us, starting in July 2021. Our editors and reviewers will focus on producing high-quality peer reviews that will be made public alongside the preprints. This announcement came amid increasing support for preprints within the life sciences and medical communities, and against the backdrop of the global COVID-19 pandemic, which led to a significant growth in preprinted research relating to the disease.

In November, we appointed two new Deputy Editors in Medicine – Diane Harper and Mone Zaidi – who joined our leadership team to oversee the journal’s expansion into medical research.

Now, we are pleased to take the next steps in this expansion and support for our new publishing model by integrating medRxiv – the preprint server for health sciences – into our submission process. This follows our similar work with bioRxiv in 2016 and 2017. With the support of eJournalPress and medRxiv, authors can submit their preprint to medRxiv and have it transferred to eLife for consideration at the same time. Alternatively, authors can choose to send their manuscript from the eLife submission system directly to medRxiv. eLife is the first journal to facilitate this kind of bidirectional integration with medRxiv into its process, as we lead the way into transforming medical publishing.

For medical research that authors submit to eLife first, we plan to send their preprint directly to medRxiv during the full submission process, just after our editors invite the paper for peer review. We will send the merged PDF, as well as metadata including the title, author names, competing interests, data availability and funding statements, and details on the study registration to medRxiv as soon as submissions pass our staff checks.

For authors who submit to medRxiv first, they can choose to also send their work for consideration by eLife using medRxiv’s direct transfer service from their Author Area. The corresponding author then receives a link whereby they can upload a cover letter and complete their submission to eLife.

Until July this year, we will give authors the option to opt out of our default process when they submit to the journal and explain their reasons, so we can understand and try to alleviate their concerns in the future. We then plan to only review research that has been posted as a preprint as we optimise peer review for the digital age. We look forward to working with both medRxiv and bioRxiv to improve the publication and review process for our medical and scientific communities alike.


Questions and comments are welcome. Please annotate publicly on the article or contact us at hello [at] elifesciences [dot] org.

For the latest news from eLife, sign up to receive our bi-monthly newsletter. You can also follow @eLife on Twitter.